5-(Piperazin-1-yl)benzofuran-2-Carboxamide CAS 183288-46-2 Purity >99.0% (HPLC)

Short Description:

Name: 5-(Piperazin-1-yl)benzofuran-2-Carboxamide

CAS: 183288-46-2

Purity: >99.0% (HPLC)

Appearance: Light Yellow to Yellow Powder

Intermediate of API (CAS: 163521-08-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Related Intermediates
5-Cyanoindole CAS 15861-24-2
3-(4-Chlorobutyl)-5-Cyanoindole CAS 143612-79-7
Ethyl 5-Nitrobenzofuran-2-Carboxylate CAS 69604-00-8
Ethyl 5-Aminobenzofuran-2-Carboxylate CAS 174775-48-5
5-(Piperazin-1-yl)benzofuran-2-Carboxamide CAS 183288-46-2
CAS 163521-08-2

Chemical Properties:

Chemical Name	5-(Piperazin-1-yl)benzofuran-2-Carboxamide
Synonyms	5-(1-Piperazinyl)benzofuran-2-Carboxamide; 1-(2-Aminocarbonylbenzofuran-5-yl)piperazine
CAS Number	183288-46-2
CAT Number	RF-PI1498
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H15N3O2
Molecular Weight	245.28
Melting Point	>215℃ (dec.)
Density	1.268
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Light Yellow to Yellow Powder
Purity / Analysis Method	>99.0% (HPLC)
Loss on Drying	<1.00%
Residue on Ignition	<0.50%
Total Impurities	<1.00%
1 H NMR Spectrum	Consistent With Structure
Test Standard	Enterprise Standard
Usage	Intermediate of API (CAS: 163521-08-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

5-(Piperazin-1-yl)benzofuran-2-Carboxamide (CAS: 183288-46-2) is an intermediate in the synthesis of API (CAS: 163521-08-2). (CAS: 163521-08-2) is a selective serotonin reuptake inhibitor (SSRI) and partial serotonin receptor agonist which is used in the therapy of major depressive disorders. (CAS: 163521-08-2) is a serotonergic antidepressant, was approved by the FDA for use in the United States to treat major depressive disorder in 2011. The mechanism of the antidepressant effect of (CAS: 163521-08-2) is not fully understood but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake.